Eliquis phase 3 study results

Results from the six month phase 3 AMPLIFY trial of 5,395 patients with acute venous thromboembolism (VTE), which included symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE), have recently been announced. In this trial, apixaban as a single-agent achieved the primary efficacy endpoint of non-inferiority to conventional therapy (transition from initial parenteral enoxaparin to warfarin therapy) in the reduction of the composite endpoint of recurrent symptomatic VTE or VTE-related death.Apixaban also met the primary safety endpoint of superiority for major bleeding, with a 69% relative risk reduction (RRR) compared to conventional therapy (absolute risk reduction [ARR] 1.2%; p